KYORIN Pharmaceutical (4569) · InitiativeRestated
Full-Scale Operation of the Takaoka Formulation Research Center and Strengthening Generic Formulation Development
First written in FY2018-Q1. 1 of 2 entries say "Restated". Latest entry: FY2018-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Full-scale launch of the Takaoka Formulation Research Institute and strengthening of the generic formulation development platformA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018-Q2RestatedAnnual report
「Kyorin Remedio Co., Ltd. commenced full-scale operations in July 2017 at the new Takaoka Drug Formulation Research Center established at Takaoka Office Park.」
The company continues to describe the full-scale operation of the Takaoka Drug Formulation Research Center from July 2017 and its use in generic formulation development. - FY2018-Q1First statedAnnual report
「KYORIN Remedio Co., Ltd. established a new research facility, the Takaoka Formulation Research Center, in Takaoka Office Park, and commenced full-scale operations on 3 July 2017. To achieve the priority strategy of promoting a distinctive generic pharmaceutical business, we will use the center to strengthen generic formulation development capabilities and increase the number of attractive products developed in-house.」
The Takaoka Formulation Research Center began full-scale operations on 3 July 2017 and is being used to strengthen generic formulation development and in-house product development.